Hence, our studies uncover that the interference with MAPK/ERK/CBP-RFPL-3/hTERT pathway may be used as a potential therapeutic strategy to reduce ASC-stimulated proliferation of breast cancer cells. This evidence concerns the gene RFPL3 and breast cancer.